Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Biogen announced that litifilimab, an anti‑BDCA2 monoclonal antibody, achieved its primary endpoint in the Phase 2 portion of the AMETHYST study for cutaneous lupus erythematosus (CLE). The drug showed an 11.8% greater reduction in disease activity versus placebo, with 14.7% of patients reaching clear or almost clear skin by week 16. Safety was comparable to placebo, and the trial reinforced the FDA Breakthrough Therapy Designation previously granted. Results were presented at the 2026 American Academy of Dermatology meeting.
Adam, I used to think this way. Then gene therapy & IO worked. IL2 has consumed a lot of hope; but new variations make it hard to quit. Abeta worked. And synergy: combine modest drugs, unlock big benefits. Invest or...
A comprehensive atlas now defines all human E3 ligases, resolving decades of inconsistencies and providing a unified framework to advance research and therapeutic development for diseases linked to these essential enzymes. biotechnology
Arrowhead Pharmaceuticals presented two‑year open‑label extension data for plozasiran at the ACC 75th session, showing an 83% median triglyceride reduction in severe hypertriglyceridemia and 96% of patients dropping below the 500 mg/dL pancreatitis threshold. No adjudicated acute pancreatitis events occurred, and...
Our first ever earnings call coming up tomorrow - we are reporting our 2025 annual results. I will start the call with the 5 minute introduction to AI drug discovery and how we measure AI drug discovery productivity. In my...
Scientists in Spain kept a donated human uterus alive for 24 hours using a machine that mimics the body's circulatory system, pumping modified blood through the organ.
The University of Texas at San Antonio has opened a precision clinical trial to evaluate rapamycin in non‑smoking, independently living seniors. Researchers hope the study will provide hard data on dosing and safety, moving the longevity drug from hype to...
A recent industry report warns that AI‑driven drug discovery platforms are vulnerable to cyber‑attacks and data‑privacy breaches, citing outdated hardware, fragmented compliance frameworks, and supply‑chain pressures. The findings could force pharma firms to overhaul security protocols and accelerate regulatory engagement.
GlucoTrack, Inc. saw its Nasdaq‑listed shares climb 34.09% to $1.46 after reporting key milestones that set the stage for an Investigational Device Exemption (IDE) filing with the FDA in the second quarter of 2026. The company completed a first‑in‑human trial...
Tanabe Pharma announced that its oral investigational drug achieved positive results in a pivotal Phase 3 trial for erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP), two ultra‑rare phototoxic disorders. The study met its primary endpoint of reducing light‑induced pain episodes and...
The HI‑PEITHO trial showed that ultrasound‑facilitated, catheter‑directed fibrinolysis combined with heparin cuts the 7‑day composite risk of PE‑related death, cardiorespiratory decompensation or collapse by 61% versus anticoagulation alone. In 544 intermediate‑risk pulmonary embolism patients, the number needed to treat was...
University of Illinois Urbana‑Champaign researchers unveiled GIS‑ROTA, a Geographic Information System‑augmented spatial transcriptomics framework that visualizes biological pathway activity inside tumors. Applied to estrogen‑receptor‑positive breast cancer, the method exposed distinct spatial patterns differentiating primary from metastatic lesions and highlighted regions...
Bristol Myers Squibb reported Phase 4 data showing that adults with schizophrenia can switch from oral atypical antipsychotics to Cobenfy (xanomeline‑trospium) without loss of symptom control. In an 8‑week open‑label trial, 86% of 105 patients completed the study, and mean PANSS...
As a medical school professor, I've watched GLP-1 drugs transform diabetes and obesity treatment. Now a Nature Cancer review reveals they may suppress cancer too. GLP-1 drugs reduce insulin resistance, lower inflammation, and cut body weight -- three of the biggest...
Researchers at Leiden University introduced microrobots only a few tens of micrometres long that can swim, steer and change shape without any onboard sensors or code, moving at roughly 7 µm per second. The breakthrough relies on a nanostructured chain design...
Lantern Pharma and its subsidiary Starlight Therapeutics received FDA clearance for the Investigational New Drug application of STAR-001, paving the way for a Phase 1 pediatric trial in central nervous system cancers. The announcement sent Lantern's Nasdaq‑listed shares down 10.04%...
Adjuvant pembrolizumab (Keytruda) continued to show a strong recurrence‑free survival (RFS) advantage in resected stage IIB/IIC melanoma, with median RFS not reached versus 59.2 months for placebo (hazard ratio 0.65). The 48‑month RFS rates were 68.7% with pembrolizumab compared with...
Oral GLP-1 wars, FDA drift, HIV franchise defense, and a few biotech landmines | Ep. 970 https://t.co/sx4kBXzgSL [ 02:30 ] oral GLP-1 battlefield heats up [ 03:08 ] convenience factor drives adoption [ 04:51 ] tolerability issues hit persistence [ 05:45 ] Novo writes $2.1...
Recent meta‑analyses of roughly 100,000‑plus adults confirm that statins and other cholesterol‑lowering drugs cut cardiovascular events by about 30 percent relative risk, delivering an absolute 2 percent mortality benefit over four years—equivalent to one life saved for every 50 treated. The safety...
The U.S. Food and Drug Administration approved Novo Nordisk’s 7.2 mg semaglutide injection, branded Wegovy HD, just 54 days after filing. The fast-track decision, the fourth under the National Priority Voucher program, expands dosing options for weight‑loss and metabolic biohackers.
Researchers from Northwestern, Rice and Carnegie Mellon unveiled HOBIT, a gum‑sized implant that keeps engineered cells alive and releases three biologics—an anti‑HIV antibody, a GLP‑1 peptide and leptin—for a month in animal trials. The device maintained 65% cell viability versus...
Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration granted accelerated approval for KRESLADI, its one‑time gene therapy for severe leukocyte adhesion deficiency‑I in children. The milestone triggered a swing in the company's stock, with a pre‑market surge followed...
Spanish researchers at the Carlos Simon Foundation have kept a donated human uterus alive outside the body for 24 hours using a normothermic perfusion device called “Mother” (PUPER). The machine circulates oxygenated, nutrient‑rich blood through the organ, mimicking natural circulation. This...
It’s interesting how quickly the conversation has shifted. Not long ago, people were hesitant about weight loss injections. Now the question is whether GLP-1s should be used… for longevity. That shift alone is worth paying attention to. Because it reflects something deeper — we’re...
TTN shows up as one of the most mutated genes in almost every cancer exome. New bioinformaticians see it and think they found something. They didn't. It's a 364-exon gene encoding the largest human protein. It collects mutations like a lint...
Researchers at the National Laboratory of the Rockies (NLR) are advancing "cell‑free" biomanufacturing, using curated enzyme cocktails instead of living microbes to convert biomass into chemicals. By pairing high‑throughput robotics with machine‑learning analytics, they can evaluate thousands of enzyme variants...
β-Hydroxybutyrate, a primary metabolite of ketogenic diets and its dual role in modulating colorectal cancer: from molecular mechanisms to therapeutic insights https://t.co/pPCdm2AcFo https://t.co/mPtz1Xqiep
Scientists have identified a direct brain pathway—via the ventromedial hypothalamus and the Rap1 protein—through which metformin improves glucose regulation. The discovery reframes the 60‑year‑old diabetes drug as a potential low‑cost biohack for brain health and lifespan extension.
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development Who is winning AI race again? https://t.co/ZW4S2zUGkS
Stanford University scientists have mapped a neural‑immune pathway by which the age‑associated bacterium Parabacteroides goldsteinii provokes gut inflammation, disrupts vagus‑nerve signaling and degrades hippocampal memory function in mice. The finding suggests dietary or microbiome‑based interventions could become a lever for...
China Shineway Pharmaceutical Group Limited announced a full‑year net profit of RMB949.95 million (about $133 million), up from RMB840.05 million a year earlier. The gain came even as revenue slipped 17% to RMB3.135 billion ($439 million), highlighting a mixed performance in China's generic drug market.
Cell and gene therapy (CGT) manufacturing is advancing quickly, yet many early‑stage firms postpone building an integrated digital backbone. The resulting manual handoffs create safety, compliance, and scalability risks. SAP’s Cell and Gene Therapy Orchestration platform introduces guided workflows, e‑signatures,...
Ocugen announced completion of patient enrollment for its Phase 3 liMeliGhT trial of OCU400, a modifier gene therapy for retinitis pigmentosa. The study enrolled 140 patients in a 2:1 treatment‑to‑control ratio and will assess visual function via the LDNA mobility test....
A recent study demonstrates that promoter methylation of four genes—MAX, MTURN, HLA‑B and CAV1—can be detected in plasma circulating cell‑free DNA and used as a non‑invasive biomarker for lung cancer. In tumor tissue, MAX, MTURN and HLA‑B showed hypermethylation rates...
SELLAS Life Sciences announced it will present preclinical data on its CDK9 inhibitor SLS009 (tambiciclib) at the AACR 2026 meeting in San Diego. The poster highlights the drug’s ability to induce apoptosis and lower MCL‑1 levels in acute myeloid leukemia...
For years, we’ve talked about a trillion-dollar bioeconomy. The harder question has always been where to start. This new piece on the AB4S Molecule Manifesto from @LOrealGroupe, @Lallemande, @EITFood , @BASF, @Evonik, and @cradlebio offers one of the most compelling answers...
Now THAT is some strong RUBY expression. Filtering transgenic callus a heap of times really pays off. Chasing the red hue without any herbicide or antibiotic pressure. Just hormones to induce callus and careful scalpel work. Some German Chammomile for...
New real‑world analysis of 482 acute myeloid leukemia patients shows tyrosine kinase inhibitors produce comparable overall survival and event‑free survival across racial and ethnic groups. The study, using the Flatiron Health Research Database from 2015‑2023, captured patients treated with FLT3,...
Researchers at Keio University discovered that intestinal epithelial cells (IECs) expressing MHC class II trigger the expansion of pathogenic Th17 cells that migrate to the spinal cord and drive neuroinflammation in multiple sclerosis (MS) mouse models. Examination of intestinal biopsies from...
Rosen Law Firm has filed a securities‑fraud class action against Corcept Therapeutics and opened a class‑action investigation into Aldeyra Therapeutics following FDA setbacks. The actions give investors a chance to seek compensation and set a deadline of April 21, 2026...
“Huntington’s Disease and The Triad of Therapeutic Conviction”. Debut blog from Eric Green, CEO of Trace Neuro, explaining why and how advances are happening in HD. Genetics, cellular understanding, and enabling modalities. https://t.co/pAr9EQs5gJ
Researchers at Ruhr University Bochum, Houston Methodist and the University of Johannesburg have unveiled three nanomedicine platforms—a light‑activated copper nanoparticle, a magnetically guided superparamagnetic carrier and a liposome‑encapsulated photodynamic therapy—that each claim to dramatically improve precision for cancer or spinal‑cord...
Modern Dental Group Ltd announced full‑year earnings of HK$596.97 million, a 46% increase from the prior year, with revenue climbing 11.1% to HK$3.74 billion. The results arrive as the company faces a packed FDA calendar that could unlock further market opportunities for...
This is so awesome. @JohnSchloendorn and Alice Gilman at R3 Bio talk through what they’re doing at R3 Bio: building something that's never existed before. They're designing genetically engineered whole organ systems. See them featured in WIRED. @WIRED full story here: https://t.co/8z5iGXR0uK
![[Comment] New Hope for Neurotrophin Targeting in Osteoarthritis Pain?](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/754aaf1faeb0d5f3b76618daddf79401.webp)
Osteoarthritis (OA) remains a massive global health challenge with no disease‑modifying drugs and only modestly effective analgesics. The anti‑NGF monoclonal antibody, introduced in 2010, delivered unprecedented pain relief but was halted in 2021 after the FDA and EMA flagged joint...
![[Editorial] Politicisation of the US FDA: Eroding Integrity and Trust](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/2cbcac9eecf69b15e3915028747699be.webp)
The editorial warns that increasing political interference is eroding the US Food and Drug Administration’s integrity and public trust. With a 2026 budget of $6.8 billion, the FDA remains the world’s most influential drug regulator, tasked with safeguarding safety while accelerating...
Brown fat loses its heat-producing function with age due to epigenetic changes that reduce activity of key genes like PGC1A, with specific enhancers playing a critical role in maintaining this function. https://t.co/Dnnawd5r41
MiniMed secured FDA clearance for the MiniMed Flex, its smallest insulin pump yet, featuring a fully smartphone‑controlled, screenless design. The pocket‑sized device is roughly half the size of the 780G and holds a 300‑unit insulin reservoir while integrating continuous glucose...
LEO Pharma presented long‑term results from the five‑year EFFISAYIL ON extension, showing subcutaneous SPEVIGO® reduced generalized pustular psoriasis (GPP) flares from an average of two per year to 0.13, with 74.6% of patients experiencing no flares over three years. Intravenous SPEVIGO...
Korean biotech is gaining global visibility after the East‑West Biopharma Summit highlighted its first‑in‑class pipelines. The Korean Ministry of Health and Welfare announced that Eli Lilly will invest $500 million over the next five years to collaborate with domestic firms. The deal...
